Medical/Pharmaceuticals

Berlin Heals Announces Publication of Two-Year Clinical Outcomes of Cardiac Microcurrent Therapy in ESC Heart Failure

Study shows sustained improvements in heart failure symptoms and function following long-term C-MIC therapy ZUG, Switzerland, July 16, 2025 /PRNewswire/ -- Berlin Heals, a pioneer in bioelectric medicine for the treatment of heart failure, is pleased to announce the publication of a new peer-re...

2025-07-16 15:00 1445

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Pidnarulex (CX-5461) has been selected by the U...

2025-07-16 10:32 2274

Fujitsu and Acer Medical trial AI service that assesses future disease risk in elderly patients through gait pattern abnormality detection

TOKYO, July 16, 2025 /PRNewswire/ -- Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a collaborative agreement to develop "aiGait" powered by Uvance, a solution that leverages Fujitsu's advanced skeleton recognition AI tec...

2025-07-16 10:04 1998

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastati...

2025-07-16 09:47 2238

ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network,ziresovir (10mg) has been included in ...

2025-07-16 09:00 2705

PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test

* FebriDx® is a first-in-class rapid test that differentiates between bacterial and non-bacterial respiratory infections, offering significant potential to address critical unmet needs in patient care by enabling more informed antibiotic use and aiding in the reduction of antimicrobial resistan...

2025-07-16 08:54 2062

Avio Health Launches AI Platform to Turn Disconnected Health Data into Preventive Intelligence

How Avio Health Is Rewiring Medicine for the Age of AI PALO ALTO, Calif. , July 15, 2025 /PRNewswire/ -- Today, Avio Health announced the launch of its proprietary clinical AI platform, which is designed to unify health data and support the shift toward preventative, personalized care. By integr...

2025-07-15 21:41 1661

Introducing the VARON VP-8G: A Smarter, Lighter Portable Oxygen Concentrator Built for Life on the Move

NEW YORK, July 15, 2025 /PRNewswire/ -- For those who need reliable oxygen support without compromising mobility,VARON proudly introduces the VP-8G portable oxygen concentrator

2025-07-15 20:25 1304

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Nietham...

2025-07-15 19:30 1730

Lung Scan Technology Reveals Hidden Secrets of Airway Disease

Scientists Unveil 4DMedical Imaging Breakthrough that Spots Early Lung Disease Missed by Standard Tests LOS ANGELES, July 15, 2025 /PRNewswire/ -- Researchers at Vanderbilt University, Johns Hopkins University, University of Miami, and The Alfred Hospital studied the lungs of subjects including ...

2025-07-15 19:07 1786

Argon Medical Streamlines Distribution of Product and Enhances Customer Training for Europe, Asia, and Africa with the Debut of a Modern, Mixed-Use Facility

PLANO, Texas, July 15, 2025 /PRNewswire/ -- Argon Medical, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announces the grand opening of its new Distribution & Education Center (ADEC), strategicall...

2025-07-15 17:12 1804

AXA and China Biotech Services Sign Memorandum of Understanding

Joint effort to explore innovative cancer treatment solutions and broaden options for customers HONG KONG, July 15, 2025 /PRNewswire/ -- AXA China Region Insurance Company (Bermuda) Limited, together with AXA International Reinsurance (Shanghai) Company Limited ("AXA"), is pleased to announce th...

2025-07-15 15:23 2198

Baraya Extended Care Closes Series B Funding Round Bringing Total Capital Raised to USD 124 Million from TVM Capital Healthcare and a Syndicate of Prominent Investors

 TVM Capital Healthcare's oversubscribed fundraise for Baraya Extended Care addresses critical gaps in long-term care, supporting Saudi Arabia's Vision 2030 healthcare goals. DUBAI, UAE and  RIYADH, Saudi Arabia, July 15, 2025 /PRNewswire/ -- TVM Capital Healthcare announces the closing of a Ser...

2025-07-15 14:00 1858

Baraya Extended Care Closes Series B Funding Round Bringing Total Capital Raised to USD 124 Million from TVM Capital Healthcare and a Syndicate of Prominent Investors

 TVM Capital Healthcare's oversubscribed fundraise for Baraya Extended Care addresses critical gaps in long-term care, supporting Saudi Arabia's Vision 2030 healthcare goals. DUBAI, UAE and  RIYADH, Saudi Arabia, July 15, 2025 /PRNewswire/ -- TVM Capital Healthcare announces the closing of a Ser...

2025-07-15 14:00 1634

Divamics' AI and Molecular Dynamics Platform Powers Breakthroughs in Metabolic Disease Drug Discovery for Partners

SUZHOU, China, July 15, 2025 /PRNewswire/ -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through its advanced AI and molecular dynamics(MD) platform. This powerful platform recently supported the successful design of B...

2025-07-15 07:31 1814

Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

-          The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously administered ASC47 (half-life up to 40 days) in combination with four doses of semaglutide (0.5 mg, onc...

2025-07-15 07:00 2110

Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma

BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the s...

2025-07-15 04:05 1984

LABCONNECT APPOINTS MITCHELL BLUMENFELD AS CHIEF FINANCIAL OFFICER

JOHNSON CITY, Tenn., July 15, 2025 /PRNewswire/ -- LabConnect is pleased to announce the appointment of Mitch Blumenfeld as its Chief Financial Officer, effective August 4, 2025. Mitch joins LabConnect with proven experience as Chief Financial Officer for high-growth companies in multiple industr...

2025-07-15 02:56 1853

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

* Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model * Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth * Creates a combined company with ...

2025-07-14 19:00 2537

Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform

* Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D * Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14,...

2025-07-14 15:38 1564
1 ... 77787980818283 ... 644